125 related articles for article (PubMed ID: 38821442)
1. Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: a case series.
Ben-Sassi K; Sarwar S
J Glob Antimicrob Resist; 2024 May; ():. PubMed ID: 38821442
[TBL] [Abstract][Full Text] [Related]
2. Outpatient parenteral antibiotic therapy (OPAT) and inpatient treatment strategies for emergency department patients with cellulitis: a cost analysis.
Yadav K; Kumar S; Chhabra S; Rosenberg H; Eagles D; Suh KN; Ohle R; Nath A; Thavorn K
CJEM; 2022 Aug; 24(5):520-528. PubMed ID: 35675027
[TBL] [Abstract][Full Text] [Related]
3. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
J Emerg Med; 2024 Mar; ():. PubMed ID: 38825531
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
[TBL] [Abstract][Full Text] [Related]
5. Evaluating an admission avoidance pathway for children in the emergency department: outpatient intravenous antibiotics for moderate/severe cellulitis.
Ibrahim LF; Hopper SM; Connell TG; Daley AJ; Bryant PA; Babl FE
Emerg Med J; 2017 Dec; 34(12):780-785. PubMed ID: 28978652
[TBL] [Abstract][Full Text] [Related]
6. The impact of an outpatient parenteral antibiotic therapy (OPAT) clinic for adults with cellulitis: an interrupted time series study.
Yadav K; Mattice AMS; Yip R; Rosenberg H; Taljaard M; Nemnom MJ; Ohle R; Yan J; Suh KN; Stiell IG; Eagles D
Intern Emerg Med; 2021 Oct; 16(7):1935-1944. PubMed ID: 33515424
[TBL] [Abstract][Full Text] [Related]
7. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
[TBL] [Abstract][Full Text] [Related]
8. Use of a telehealth follow-up system to facilitate treatment and discharge of emergency department patients with severe cellulitis.
Koziatek C; Klein N; Mohan S; Lakdawala V; Swartz J; Femia R; Press R; Caspers C
Am J Emerg Med; 2021 Mar; 41():184-189. PubMed ID: 32081554
[TBL] [Abstract][Full Text] [Related]
9. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.
Bai F; Mazzitelli M; Silvola S; Raumer F; Restelli U; Croce D; Marchetti G; Cattelan AM
JAC Antimicrob Resist; 2023 Apr; 5(2):dlad044. PubMed ID: 37090914
[TBL] [Abstract][Full Text] [Related]
11. Predictors of failure of empiric outpatient antibiotic therapy in emergency department patients with uncomplicated cellulitis.
Peterson D; McLeod S; Woolfrey K; McRae A
Acad Emerg Med; 2014 May; 21(5):526-31. PubMed ID: 24842503
[TBL] [Abstract][Full Text] [Related]
12. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol.
Durante-Mangoni E; Riccardi A; Guarino M; Cesaro F; Lugarà M; Mascolo S; Morelli L; Natale V; Andreoni M
J Chemother; 2023 Sep; 35(5):397-403. PubMed ID: 36264157
[TBL] [Abstract][Full Text] [Related]
13. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
Jensen IS; Wu E; Fan W; Lodise TP; Nicolau DP; Dufour S; Cyr PL; Sulham KA
J Manag Care Spec Pharm; 2016 Jun; 22(6):752-64. PubMed ID: 27231802
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis.
Ibrahim LF; Huang L; Hopper SM; Dalziel K; Babl FE; Bryant PA
Lancet Infect Dis; 2019 Oct; 19(10):1101-1108. PubMed ID: 31420292
[TBL] [Abstract][Full Text] [Related]
15. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
[TBL] [Abstract][Full Text] [Related]
16. Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore.
Chan M; Ooi CK; Wong J; Zhong L; Lye D
BMC Infect Dis; 2017 Jul; 17(1):474. PubMed ID: 28683717
[TBL] [Abstract][Full Text] [Related]
17. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.
Baltin CT; Wulf C; Rongisch R; Lehmann C; Wingen-Heimann S; Eisenmenger N; Bonn J; Fabri M; von Stebut E; Cornely OA; Kron F
J Infect Public Health; 2023 Jun; 16(6):955-963. PubMed ID: 37099955
[TBL] [Abstract][Full Text] [Related]
18. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
McSorley JC; Reyes D; Tonna I; Bateman V
Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
[TBL] [Abstract][Full Text] [Related]
20. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.
Wilke M; Worf K; Preisendörfer B; Heinlein W; Kast T; Bodmann KF
GMS Infect Dis; 2019; 7():Doc03. PubMed ID: 31728264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
